Another first-in-human mystery from Merck
MK-8294 starts phase 1, but its mechanism is anybody's guess.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
The FDA's "radical transparency", up to a point
A newly published cache of CRLs includes six novel oncology drugs.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
AbbVie steps up for Glenmark's multispecific
The deal for ISB 2001 is worth $700m up front.
Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
When two antigens are better than one
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
